Table 1.
Seroadaptive measures | SPARM | SAM | SPROM |
---|---|---|---|
Comparison group | 1.50 (1.09, 1.99) | 0.78 (0.56, 1.07) | 1.48 (1.22, 1.77)* |
| |||
Time | |||
Followup 1 | 1.55 (1.10, 2.09) | 0.74 (0.52, 1.03) | 1.71 (1.36, 2.14)* |
Followup 2 | 1.56 (1.10, 2.12) | 0.67 (0.46, 0.93)* | 1.80 (1.41, 2.28)* |
Followup 3 | 1.58 (1.11, 2.16) | 0.73 (0.51, 1.02) | 1.69 (1.30, 2.15)* |
Followup 4 | 1.47 (1.05, 2.00) | 0.72 (0.50, 1.00)* | 1.82 (1.39, 2.32)* |
Followup 5 | 1.32 (0.93, 1.78) | 0.88 (0.60, 1.23) | 1.87 (1.44, 2.39)* |
| |||
Treatment (Trt) | |||
Trt Baseline | 1.55 (1.10, 2.10) | 0.82 (0.59, 1.13) | 1.42 (1.16, 1.73)* |
Trt Followup 1 | 1.48 (1.05, 2.03) | 0.80 (0.56, 1.12) | 1.62 (1.28, 2.03)* |
Trt Followup 2 | 1.39 (0.98, 1.91) | 0.82 (0.57, 1.15) | 1.82 (1.42, 2.32)* |
Trt Followup 3 | 1.41 (1.00, 1.94) | 0.82 (0.56, 1.15) | 1.91 (1.47, 2.49)* |
Trt Followup 4 | 1.23 (0.87, 1.69) | 0.90 (0.61, 1.27) | 1.83 (1.33, 2.44)* |
Trt Followup 5 | 1.35 (0.95, 1.87) | 0.88 (0.58, 1.24) | 1.75 (1.31, 2.30)* |
| |||
Risk Group | |||
FEM | 4.26 (2.89, 5.93) | 0.72 (0.49, 1.02) | 1.44 (1.14, 1.73)* |
HTM | 2.05 (1.37, 2.93) | 0.86 (0.56, 1.28) | 1.48 (1.08, 1.95)* |
IDU | 0.96 (0.65, 1.34) | 0.69 (0.45, 1.00)* | 1.31 (1.10, 1.54)* |
| |||
Race | |||
Black | 1.35 (0.99, 1.79) | 0.79 (0.58, 1.05) | 1.27 (1.01, 1.57)* |
Hispanic | 2.02 (1.47, 2.72) | 0.75 (0.55, 1.01) | 1.52 (1.18, 1.92)* |
Other | 1.59 (1.07, 2.28) | 0.75 (0.51, 1.06) | 1.53 (1.18, 1.93)* |
| |||
Location | |||
Milwaukee | 3.16 (2.09, 4.65) | 0.76 (0.49, 1.11) | 1.58 (1.26, 1.93)* |
New York | 1.36 (0.95, 1.87) | 0.89 (0.63, 1.25) | 1.64 (1.27, 2.02)* |
San Francisco | 1.77 (1.26, 2.37) | 0.82 (0.58, 1.13) | 1.51 (1.25, 1.81)* |
Values of SAM and SPROM with * indicate statistically significant evidence for seroadaptation.
Values in bold are significantly different from the value in the comparison group.